We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.99B
1-Year Est. Return 737.95%
This Fund
S&P 500
This Quarter Est. Return
+14.19%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$689M
AUM Growth
-$53.2M
Cap. Flow
-$90.8M
Cap. Flow %
-13.19%
Top 10 Hldgs %
41.31%
Holding
80
New
3
Increased
6
Reduced
50
Closed
5

Top Buys

Rank Stock Value
1
ANAB icon
AnaptysBio
ANAB
+$20.9M
2
JUNO
Juno Therapeutics, Inc.
JUNO
+$13.9M
3
JNCE
Jounce Therapeutics, Inc. Common Stock
JNCE
+$9.22M
4
FWP
Forward Pharma A/S American Depositary Shares
FWP
+$6.73M
5
CHRS icon
Coherus Oncology
CHRS
+$2.49M

Top Sells

Rank Stock Value
1
NVRO
NEVRO CORP.
NVRO
+$22.7M
2
EGRX
Eagle Pharmaceuticals, Inc.
EGRX
+$15.6M
3
ALDR
Alder Biopharmaceuticals
ALDR
+$10.7M
4
HRTX icon
Heron Therapeutics
HRTX
+$10.4M
5
BPMC
Blueprint Medicines
BPMC
+$8.66M

Sector Composition

Rank Sector Weight
1 Healthcare 86.78%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TBPH icon
1
Theravance Biopharma
TBPH
$873M
$52.5M 7.62%
1,425,000
– –
NVRO
2
DELISTED
NEVRO CORP.
NVRO
$32.8M 4.76%
350,000
-251,044
-42% -$22.7M
KA
3
DELISTED
Kineta, Inc. Common Stock
KA
$29.7M 4.32%
27,172
– –
LKFT
4
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.82B
$26.1M 3.79%
300,000
-34,044
-10% -$2.45M
ANAB icon
5
AnaptysBio
ANAB
$1.54B
$24.9M 3.61%
+895,626
New +$20.9M
ARDX icon
6
Ardelyx
ARDX
$1.24B
$24.3M 3.53%
1,922,738
-149,226
-7% -$1.96M
BPMC
7
DELISTED
Blueprint Medicines
BPMC
$24M 3.48%
600,000
-241,752
-29% -$8.66M
ACRS icon
8
Aclaris Therapeutics
ACRS
$715M
$23.9M 3.46%
800,000
-176,286
-18% -$5.08M
PTLA
9
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$23.5M 3.41%
600,000
+63,000
+12% +$2.01M
ALDR
10
DELISTED
Alder Biopharmaceuticals
ALDR
$22.8M 3.32%
1,098,205
-483,399
-31% -$10.7M
QTNT
11
DELISTED
Quotient Limited Ordinary Shares
QTNT
$20.3M 2.94%
72,475
-1,025
-1% -$262K
NERV icon
12
Minerva Neurosciences
NERV
$191M
$18.7M 2.71%
288,488
-43,067
-13% -$3.34M
HRTX icon
13
Heron Therapeutics
HRTX
$93.4M
$18M 2.61%
1,200,000
-751,263
-39% -$10.4M
EGRX
14
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
$16.6M 2.41%
200,000
-210,000
-51% -$15.6M
CLSD
15
DELISTED
Clearside Biomedical
CLSD
$15.4M 2.24%
129,392
-26,164
-17% -$3.09M
MYOK
16
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$14.9M 2.16%
1,130,000
-315,090
-22% -$4.04M
JUNO
17
DELISTED
Juno Therapeutics, Inc.
JUNO
$14.4M 2.09%
+650,000
New +$13.9M
CRBP icon
18
Corbus Pharmaceuticals
CRBP
$165M
$13.9M 2.02%
56,203
-27,130
-33% -$6.66M
WVE icon
19
Wave Life Sciences
WVE
$1.12B
$13.3M 1.93%
482,079
-25,828
-5% -$721K
CHRS icon
20
Coherus Oncology
CHRS
$217M
$13.1M 1.9%
620,300
+101,210
+19% +$2.49M
NBIX icon
21
Neurocrine Biosciences
NBIX
$18.2B
$13M 1.89%
300,000
-59,000
-16% -$2.53M
FWP
22
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
$12.7M 1.84%
84,168
+35,714
+74% +$6.73M
OMER icon
23
Omeros
OMER
$845M
$11.3M 1.65%
750,000
-225,000
-23% -$2.46M
ZYNE
24
DELISTED
Zynerba Pharmaceuticals, Inc
ZYNE
$10.1M 1.46%
500,000
+19,499
+4% +$387K
CBPO
25
DELISTED
China Biologic Products Holdings, Inc.
CBPO
$10M 1.45%
100,000
-12,867
-11% -$1.37M
1
2 3 4

Similar funds

SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
CCA
Checchi Capital Advisers Beverly Hills, California $1.98B AUM 19.17% 1-Year Est. Return
LBC
Lowe Brockenbrough & Co Richmond, Virginia $2.01B AUM 22.05% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return

Cormorant Asset Management's Q1 2017 Portfolio in Review

As of Q1 2017, Cormorant Asset Management held 80 positions worth $689M, down 7.2% from $742M the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Cormorant Asset Management withdrew a net $90.8M in Q1 2017, closing 5 positions and reducing 50 holdings. Its most notable exit was Concert Pharmaceuticals, Inc., an estimated $5.54M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, down from 91% a quarter earlier.

Against the trend, Cormorant Asset Management opened a new position in AnaptysBio worth $24.9M.

  • Cormorant Asset Management's largest Q1 2017 buy was AnaptysBio: 895,626 shares worth $24.9M.
  • Cormorant Asset Management added most to Forward Pharma A/S American Depositary Shares in Q1 2017, an estimated $6.73M increase.
  • Cormorant Asset Management's biggest Q1 2017 reduction was NEVRO CORP., cutting an estimated $22.7M.
  • Cormorant Asset Management fully exited Concert Pharmaceuticals, Inc. in Q1 2017, selling an estimated $5.54M.
  • Cormorant Asset Management's ten largest holdings make up 41% of its $689M portfolio in Q1 2017.
  • Cormorant Asset Management opened 3 new positions and closed 5 in Q1 2017.
  • Cormorant Asset Management's portfolio value fell 7.2% quarter-over-quarter to $689M.

Based on Cormorant Asset Management's 13F filing for Q1 2017, filed 15 May 2017.